Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.
M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M. M'Baloula J, et al. Among authors: doat s. Eur J Cancer. 2024 Nov;212:115051. doi: 10.1016/j.ejca.2024.115051. Epub 2024 Oct 1. Eur J Cancer. 2024. PMID: 39366210 Free article.
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Coutzac C, Trouilloud I, Artru P, Henriques J, Masson T, Doat S, Bouché O, Coriat R, Saint A, Moulin V, Vernerey D, Gallois C, De La Fouchardière C, Tougeron D, Taieb J. Coutzac C, et al. Among authors: doat s. Clin Colorectal Cancer. 2022 Jun;21(2):132-140. doi: 10.1016/j.clcc.2021.12.003. Epub 2022 Feb 14. Clin Colorectal Cancer. 2022. PMID: 35337742
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.
Gallois C, Bergen ES, Auclin É, Pernot S, Higué J, Trouilloud I, Touchefeu Y, Turpin A, Mazard T, Sartore-Bianchi A, Prenen H, Alberti A, Pilla L, Cuissy S, Wookey V, Perret A, Melchior C, Artru P, Dubreuil O, Drouillard A, Doat S, Lavolé J, Basile D, Perkins G, Jary M, Stintzing S, Ros J, Tougeron D, Taieb J. Gallois C, et al. Among authors: doat s. ESMO Open. 2024 Sep;9(9):103696. doi: 10.1016/j.esmoop.2024.103696. Epub 2024 Sep 9. ESMO Open. 2024. PMID: 39255538 Free PMC article.
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. Torregrosa C, et al. Among authors: doat s. Int J Cancer. 2022 Dec 1;151(11):1978-1988. doi: 10.1002/ijc.34166. Epub 2022 Jul 14. Int J Cancer. 2022. PMID: 35833561
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R. Palmieri LJ, et al. Among authors: doat s. Oncologist. 2020 Feb;25(2):e266-e275. doi: 10.1634/theoncologist.2019-0328. Epub 2019 Oct 2. Oncologist. 2020. PMID: 32043796 Free PMC article.
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A, Pernot S, Sigrand J, Le Malicot K, Mary F, Aparicio T, Dahan L, Caroli-Bosc FX, Lecomte T, Doat S, Marthey L, Desrame J, Lepage C, Taieb J. Lapeyre-Prost A, et al. Among authors: doat s. Clin Colorectal Cancer. 2020 Dec;19(4):285-290. doi: 10.1016/j.clcc.2020.06.003. Epub 2020 Jun 12. Clin Colorectal Cancer. 2020. PMID: 32921581 Clinical Trial.
Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study.
Palmieri LJ, Dubreuil O, Bachet JB, Trouilloud I, Locher C, Coriat R, Moryoussef F, Landi B, Perkins G, Hautefeuille V, Doat S. Palmieri LJ, et al. Among authors: doat s. Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101431. doi: 10.1016/j.clinre.2020.03.029. Epub 2020 May 11. Clin Res Hepatol Gastroenterol. 2021. PMID: 32409285 Free article.
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
Pietrasz D, Wang-Renault S, Taieb J, Dahan L, Postel M, Durand-Labrunie J, Le Malicot K, Mulot C, Rinaldi Y, Phelip JM, Doat S, Blons H, de Reynies A, Bachet JB, Taly V, Laurent-Puig P. Pietrasz D, et al. Among authors: doat s. Br J Cancer. 2022 Feb;126(3):440-448. doi: 10.1038/s41416-021-01624-2. Epub 2021 Nov 22. Br J Cancer. 2022. PMID: 34811505 Free PMC article. Clinical Trial.
24 results